Supplementary data: Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA

These are peer-reviewed supplementary tables for the article 'Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1: ICD-10 codes for other gynecological (GYN) conditionsSupplementary Table 2: Other GYN condition associated HCRU and direct costs (2021 USD) per patient per year during the follow-up period, overall and by treatment course (TC)Aim: Bacterial vaginosis (BV) is a common vaginal dysbiosis associated with adverse clinical sequelae, most notably, increased risk of sexually transmitted infections (STIs). The aims of this study were to estimate the frequency of BV recurrence, treatment patterns, other gynecological (GYN) conditions, and the associated healthcare resource utilization (HCRU) and costs among commercially insured patients in the USA. Patients & methods: Female patients aged 12–49 years with an incident vaginitis diagnosis and ≥1 pharmacy claim for a BV medication (fungal treatment only excluded) were selected from the Merative™ MarketScan commercial database (2017–2020). During a minimum 12-month follow-up, additional treatment courses, treatment patterns, frequency of other GYN conditions, and HCRU and costs were assessed. Generalized linear models were used to identify baseline predictors of total all-cause healthcare costs and number of treatment courses. Results: The study population included 140,826 patients (mean age: 31.5 years) with an incident vaginitis diagnosis and ≥1 BV medication claim. During the follow-up, 64.2% had 1 treatment course, 22.0% had 2, 8.1% had 3, and 5.8% had ≥4; 35.8% had a BV recurrence (≥2 BV medication claims). The most commonly prescribed BV medication was oral metronidazole (73.6%). Approximately 12% (n = 16,619) of patients had a new diagnosis of another GYN condition in the follow-up; 8.2% had a new STI, which were more common among patients with ≥4 treatment courses (12.9%). During follow up, total all-cause healthcare costs averaged $8987 per patient per year (PPPY) of which $470 was BV related. BV-related healthcare costs increased from $403 PPPY among those with 1 treatment course to $806 PPPY among thosewith≥4with nearly half the costs attributed to outpatient office visits. Conclusion: BV recurrence among this population represented a substantial clinical and healthcare economic burden warranting improvements in women’s healthcare.

本数据集为发表于《比较疗效研究杂志》的论文《美国商业保险女性细菌性阴道炎的治疗模式及经济负担》的同行评审补充表格。补充表格1：其他妇科（GYN）疾病的ICD-10编码；补充表格2：其他GYN疾病相关的HCRU和直接成本（2021年美元）按患者每年计算，在随访期间及按治疗课程（TC）分类。研究目的：细菌性阴道炎（BV）是一种常见的阴道菌群失调，与不良临床后果相关，尤其是性传播感染（STI）的风险增加。本研究旨在估计BV复发的频率、治疗模式、其他妇科（GYN）疾病，以及在美国商业保险患者中相关的医疗资源利用（HCRU）和成本。研究对象与方法：从Merative™ MarketScan商业数据库（2017-2020年）中选取了12-49岁女性患者，她们具有一次阴道炎诊断记录且至少有一次BV药物（仅排除真菌治疗）的药店索赔记录。在至少12个月的随访期间，评估了额外的治疗课程、治疗模式、其他GYN疾病的频率，以及HCRU和成本。使用广义线性模型来识别总全因医疗成本和治疗方案数量的基线预测因素。结果：研究人群包括140,826名患者（平均年龄：31.5岁），他们有一次阴道炎诊断记录和≥1次BV药物索赔。在随访期间，64.2%的患者有1次治疗课程，22.0%的患者有2次，8.1%的患者有3次，5.8%的患者≥4次；35.8%的患者有BV复发（≥2次BV药物索赔）。最常处方的BV药物是口服甲硝唑（73.6%）。大约12%（n = 16,619）的患者在随访期间被诊断为其他GYN疾病；8.2%的患者有新的STI，这些STI在≥4次治疗课程的患者中更为常见（12.9%）。在随访期间，总全因医疗成本平均每人每年为8987美元（PPPY），其中470美元与BV相关。BV相关的医疗成本从仅一次治疗课程患者的每人每年403美元增加到≥4次治疗课程患者的每人每年806美元，其中近一半的成本归因于门诊就诊。结论：在这个群体中，BV复发构成了重大的临床和医疗经济负担，值得提高女性的医疗保健水平。